Introduction of the pneumococcal conjugate vaccine in humanitarian and fragile contexts: Perspectives from stakeholders in four African countries

被引:0
|
作者
Dhaliwal, Baldeep K. [1 ]
Weeks, Rose [1 ]
Huber, Jasmine [1 ]
Fofana, Aminata [1 ]
Bobe, Mohamed [2 ]
Mbailamen, Antoinette Demian [3 ]
Legge, George [4 ,5 ]
Cisse, Gassim [5 ]
Shet, Anita [1 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, 415 N Washington St 535, Baltimore, MD 21231 USA
[2] Somalia Somaliland Country Off, Save Children, Mogadishu, Somalia
[3] Minist St Publ, Programme Elargi Vaccinat, Ndjamena, Chad
[4] Expanded Programme Immunisat EPI, Natl Minist Hlth, Juba, Sudan
[5] Expanded Programme Immunisat EPI, Minist Hlth & Publ Hyg, Conakry, Guinea
基金
比尔及梅琳达.盖茨基金会;
关键词
Pneumonia; pneumococcal conjugate vaccine; fragile contexts; health policy; decision-making;
D O I
10.1080/21645515.2024.2314828
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Childhood pneumonia causes a significant burden of preventable child morbidity and mortality in Chad, Guinea, Somalia/Somaliland, and South Sudan. Leaders from these countries have committed to reducing this burden and are preparing to introduce the pneumococcal conjugate vaccine (PCV) into their immunization programs. To support long-term sustainability for expected PCV introductions in settings afflicted by prolonged humanitarian crises this research explores national stakeholders' perspectives on contextual factors that may influence optimal vaccine implementation. This qualitative study used purposive sampling to identify and interview stakeholders involved in vaccine decision-making. Interview transcripts were analyzed through the framework method, an approach involving charting data into pre-populated matrices. Findings from interviews with 16 key informants from government, partner organizations, and international health agencies fit within the following four overarching themes: (1) population-level vulnerabilities to pneumonia, exacerbated by climatic risks and low levels of maternal education; (2) disease burden and the interest in enhancing surveillance to monitor vaccine impact and integrate disease control efforts; (3) policy processes, including formalizing vaccine decision-making; and (4) vaccine implementation preparation, including the conduct of robust communication campaigns, training, and cold chain upgrades. This research explores perspectives from leaders in these countries which are at pivotal moments in their journeys toward introducing PCV. Widespread commitment among leaders, in addition to financial support, will facilitate vaccine introduction. Further, fostering a shared understanding among partners about context-specific determinants of program success will help build tailored implementation strategies for each country.
引用
收藏
页数:9
相关论文
共 42 条
  • [41] Pneumonia Hospitalizations Among Young Children Before and After Introduction of Pneumococcal Conjugate Vaccine-United States, 1997-2006 (Reprinted from MMWR, vol 58, pg 1-4, 2009)
    Grijalva, C. G.
    Griffin, M. R.
    Nuorti, J. P.
    Walter, N. D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 301 (12): : 1220 - 1222
  • [42] Etiology, Presentation, and Risk Factors for Diarrheal Syndromes in 3 Sub-Saharan African Countries After the Introduction of Rotavirus Vaccines From the Vaccine Impact on Diarrhea in Africa (VIDA) Study
    Buchwald, Andrea G.
    Verani, Jennifer R.
    Keita, Adama Mamby
    Hossain, M. Jahangir
    Roose, Anna
    Sow, Samba O.
    Omore, Richard
    Doh, Sanogo
    Jones, Joquina Chiquita M.
    Nasrin, Dilruba
    Zaman, Syed M. A.
    Okoi, Catherine
    Antonio, Martin
    Ochieng, John B.
    Juma, Jane
    Onwuchekwa, Uma
    Powell, Helen
    Platts-Mills, James A.
    Tennant, Sharon M.
    Kotloff, Karen L.
    CLINICAL INFECTIOUS DISEASES, 2023, 76 : S12 - S22